FerrieresJDe FerrariGMHermansMPet al.Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. Eur J Prev Cardiol. 2018; 25: 1966–1976.
2.
LaRosaJCGrundySMWatersDDet al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med2005; 352: 1425–1435.
3.
CannonCPBlazingMAGiuglianoRPet al.Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
4.
SabatineMSGiuglianoRPKeechACet al.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017; 376: 1713–1722.
5.
PedersenFButrymovichVKelbækHet al.Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol2014; 64: 2101–2108.
6.
GalløeAMKelbækHThuesenLet al.10-Year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary stents. J Am Coll Cardiol2017; 69: 616–624.
7.
CannonCPBraunwaldEMcCabeCHet al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med2004; 350: 1495–1504.
8.
Müller-WielandDAssmannGCarmenaRet al.Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk. Eur J Prev Cardiol2016; 23: 275–281.
9.
MunkhaugenJSverreEOtterstadJEet al.Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol2017; 24: 981–989.
10.
KotsevaKDe BacquerDDe BackerGet al.Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol2016; 23: 2007–2018.
